Growth-hormone-releasing peptide (GHRP)-2 is a well-known and documented peptide, discovered in 1993, that comes from the family of GHRP . Growth hormone releasing compounds are a group of compounds, usually peptides consisting of four to seven amino acids, which induce elevated growth hormone levels in circulation . These peptides harbour the ability to stimulate and release growth hormone in the body’s circulation . In Japan, GHRP-2 is an approved pharmaceutical agent used as an intravenous injection to breast juvenile growth failure , and also for use the diagnosis of GH deficiency [4; 5]. GHRP-2 is also known as Pralmorelin .
GHRPs are known to bind to two receptors or ‘sites’, one is the GHS-R1a and the other is CD36 . Furthermore, GHRPs can decrease relative oxygen species (ROS), along with enhancing antioxidant defences and reducing inflammation . GHRP-2 (Figure 1) has the amino acid sequence: (D-Ala)-(D-β -Nal)-Ala-Trp-(D-Phe)-Lys-NH2 .
Figure 1. GHRP-2 is derived from, and belongs to, a class of growth hormone releasing peptides which play roles in stimulating the release of growth hormone (GH) along with increasing body weight across a number of animal species. In addition GHRP-2 has been previously shown to enhance the growth rate in children . Source: https://en.wikipedia.org/wiki/Pralmorelin
How it works
GHRP-2, as previously stated, is a synthetic peptide which acts as an agonist to the GHS receptor . Moreover, GHRP-2 stimulates the release of growth hormone by eliciting effects at the hypothalamic and pituitary sites .